Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 388

1.

The international St-aging system as a prognostic marker in general senior population: Findings from the EPIDOS cohort study.

Pouzoullic M, Schott AM, Sánchez-Rodríguez D, Bataille R, Annweiler C; SOCOS group.

Eur J Intern Med. 2019 Oct;68:51-54. doi: 10.1016/j.ejim.2019.07.031. Epub 2019 Aug 3.

PMID:
31387843
2.

Multiple Myeloma Exemplifies a Model of Cancer Based on Tissue Disruption as the Initiator Event.

Capp JP, Bataille R.

Front Oncol. 2018 Sep 10;8:355. doi: 10.3389/fonc.2018.00355. eCollection 2018.

3.

Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma.

Kervoëlen C, Ménoret E, Gomez-Bougie P, Bataille R, Godon C, Marionneau-Lambot S, Moreau P, Pellat-Deceunynck C, Amiot M.

Oncotarget. 2015 Sep 29;6(29):26922-34. doi: 10.18632/oncotarget.4616.

4.

The multiple myeloma bone eco-system and its relation to oncogenesis.

Bataille R.

Morphologie. 2015 Jun;99(325):31-7. doi: 10.1016/j.morpho.2015.03.002. Epub 2015 May 23. Review.

PMID:
26005000
5.

Multiple myeloma international staging system: "staging" or simply "aging" system?

Bataille R, Annweiler C, Beauchet O.

Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):635-7. doi: 10.1016/j.clml.2013.07.003. Epub 2013 Sep 11. Review.

PMID:
24035714
6.

Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells.

Chiron D, Maïga S, Surget S, Descamps G, Gomez-Bougie P, Traore S, Robillard N, Moreau P, Le Gouill S, Bataille R, Amiot M, Pellat-Deceunynck C.

Blood Cancer J. 2013 Jun 7;3:e120. doi: 10.1038/bcj.2013.18.

7.

Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells.

Surget S, Chiron D, Gomez-Bougie P, Descamps G, Ménoret E, Bataille R, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C.

Cancer Res. 2012 Sep 1;72(17):4562-73. doi: 10.1158/0008-5472.CAN-12-0487. Epub 2012 Jun 27.

8.

Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells.

Chiron D, Maïga S, Descamps G, Moreau P, Le Gouill S, Marionneau S, Ouiller T, Moreaux J, Klein B, Bataille R, Amiot M, Pellat-Deceunynck C.

Blood Cells Mol Dis. 2012 Apr 15;48(4):247-53. doi: 10.1016/j.bcmd.2012.01.006. Epub 2012 Feb 15.

PMID:
22341562
9.

Increased singlet oxygen-induced secondary ROS production in the serum of cancer patients.

Bigot E, Bataille R, Patrice T.

J Photochem Photobiol B. 2012 Feb 6;107:14-9. doi: 10.1016/j.jphotobiol.2011.11.003. Epub 2011 Nov 22.

PMID:
22169683
10.
11.

The peripheral CD138+ population but not the CD138- population contains myeloma clonogenic cells in plasma cell leukaemia patients.

Chiron D, Surget S, Maïga S, Bataille R, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C.

Br J Haematol. 2012 Mar;156(5):679-83. doi: 10.1111/j.1365-2141.2011.08904.x. Epub 2011 Oct 11. No abstract available.

PMID:
21988294
12.

ABT-737 is highly effective against molecular subgroups of multiple myeloma.

Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maïga S, Avet-Loiseau H, Bataille R, Moreau P, Le Gouill S, Pellat-Deceunynck C, Amiot M.

Blood. 2011 Oct 6;118(14):3901-10. doi: 10.1182/blood-2010-11-317438. Epub 2011 Aug 11.

PMID:
21835956
13.

Plasma beta-2 microglobulin as a marker of frailty in older adults: a pilot study.

Annweiler C, Bataille R, Ferrière N, Douillet D, Fantino B, Beauchet O.

J Gerontol A Biol Sci Med Sci. 2011 Oct;66(10):1077-9. doi: 10.1093/gerona/glr104. Epub 2011 Jul 9. No abstract available.

PMID:
21743090
14.

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Moreaux J, Klein B, Bataille R, Descamps G, Maïga S, Hose D, Goldschmidt H, Jauch A, Rème T, Jourdan M, Amiot M, Pellat-Deceunynck C.

Haematologica. 2011 Apr;96(4):574-82. doi: 10.3324/haematol.2010.033456. Epub 2010 Dec 20.

15.

BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma.

Bodet L, Ménoret E, Descamps G, Pellat-Deceunynck C, Bataille R, Le Gouill S, Moreau P, Amiot M, Gomez-Bougie P.

Br J Cancer. 2010 Dec 7;103(12):1808-14. doi: 10.1038/sj.bjc.6605981. Epub 2010 Nov 9.

16.

Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype.

Pallier A, Hillion S, Danger R, Giral M, Racapé M, Degauque N, Dugast E, Ashton-Chess J, Pettré S, Lozano JJ, Bataille R, Devys A, Cesbron-Gautier A, Braudeau C, Larrose C, Soulillou JP, Brouard S.

Kidney Int. 2010 Sep;78(5):503-13. doi: 10.1038/ki.2010.162. Epub 2010 Jun 9.

17.

Serum vitamin D concentration and short-term mortality among geriatric inpatients in acute care settings.

Annweiler C, Pochic S, Fantino B, Legrand E, Bataille R, Montero-Odasso M, Beauchet O.

Adv Ther. 2010 Apr;27(4):245-9. doi: 10.1007/s12325-010-0025-6. Epub 2010 May 14.

PMID:
20473599
18.

Phosphorothioate-modified TLR9 ligands protect cancer cells against TRAIL-induced apoptosis.

Chiron D, Pellat-Deceunynck C, Maillasson M, Bataille R, Jego G.

J Immunol. 2009 Oct 1;183(7):4371-7. doi: 10.4049/jimmunol.0901436. Epub 2009 Sep 4.

19.

Validation of UBE2C protein as a prognostic marker in node-positive breast cancer.

Loussouarn D, Campion L, Leclair F, Campone M, Charbonnel C, Ricolleau G, Gouraud W, Bataille R, Jézéquel P.

Br J Cancer. 2009 Jul 7;101(1):166-73. doi: 10.1038/sj.bjc.6605122. Epub 2009 Jun 9.

20.

TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production.

Chiron D, Pellat-Deceunynck C, Amiot M, Bataille R, Jego G.

J Immunol. 2009 Apr 1;182(7):4471-8. doi: 10.4049/jimmunol.0803113.

21.

The imbalance between Survivin and Bim mediates tumour growth and correlates with poor survival in patients with multiple myeloma.

Romagnoli M, Séveno C, Wuillème-Toumi S, Amiot M, Bataille R, Minvielle S, Barillé-Nion S.

Br J Haematol. 2009 Apr;145(2):180-9. doi: 10.1111/j.1365-2141.2009.07608.x. Epub 2009 Mar 2.

PMID:
19298592
22.

A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45.

Descamps G, Gomez-Bougie P, Venot C, Moreau P, Bataille R, Amiot M.

Br J Cancer. 2009 Jan 27;100(2):366-9. doi: 10.1038/sj.bjc.6604839.

23.

A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.

Jézéquel P, Campone M, Roché H, Gouraud W, Charbonnel C, Ricolleau G, Magrangeas F, Minvielle S, Genève J, Martin AL, Bataille R, Campion L.

Breast Cancer Res Treat. 2009 Aug;116(3):509-20. doi: 10.1007/s10549-008-0250-8. Epub 2008 Nov 20.

PMID:
19020972
24.

Impact of XIAP protein levels on the survival of myeloma cells.

Desplanques G, Giuliani N, Delsignore R, Rizzoli V, Bataille R, Barillé-Nion S.

Haematologica. 2009 Jan;94(1):87-93. doi: 10.3324/haematol.13483. Epub 2008 Nov 10.

25.

IL-21 stimulates human myeloma cell growth through an autocrine IGF-1 loop.

Ménoret E, Maïga S, Descamps G, Pellat-Deceunynck C, Fraslon C, Cappellano M, Moreau P, Bataille R, Amiot M.

J Immunol. 2008 Nov 15;181(10):6837-42.

26.

[Survivin in cancerology : molecular aspects and therapeutic applications].

Romagnoli M, Séveno C, Bataille R, Barillé-Nion S.

Med Sci (Paris). 2008 Oct;24(10):821-7. doi: 10.1051/medsci/20082410821. Review. French.

27.

Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome.

Decaux O, Lodé L, Magrangeas F, Charbonnel C, Gouraud W, Jézéquel P, Attal M, Harousseau JL, Moreau P, Bataille R, Campion L, Avet-Loiseau H, Minvielle S; Intergroupe Francophone du Myélome.

J Clin Oncol. 2008 Oct 10;26(29):4798-805. doi: 10.1200/JCO.2007.13.8545. Epub 2008 Jun 30.

PMID:
18591550
28.

Toll-like receptors: lessons to learn from normal and malignant human B cells.

Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G.

Blood. 2008 Sep 15;112(6):2205-13. doi: 10.1182/blood-2008-02-140673. Epub 2008 Jun 30. Review.

29.

Osteoclasts support the survival of human plasma cells in vitro.

Geffroy-Luseau A, Jégo G, Bataille R, Campion L, Pellat-Deceunynck C.

Int Immunol. 2008 Jun;20(6):775-82. doi: 10.1093/intimm/dxn035. Epub 2008 Apr 8.

PMID:
18397910
30.

Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.

Romagnoli M, Desplanques G, Maïga S, Legouill S, Dreano M, Bataille R, Barillé-Nion S.

Clin Cancer Res. 2007 Oct 15;13(20):6010-8.

31.

Crucial role of phosphatase CD45 in determining signaling and proliferation of human myeloma cells.

Collette M, Descamps G, Pellat-Deceunynck C, Bataille R, Amiot M.

Eur Cytokine Netw. 2007 Sep;18(3):120-6. Epub 2007 Sep 7.

32.

CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis.

Bataille R, Pellat-Deceunynck C, Robillard N, Avet-Loiseau H, Harousseau JL, Moreau P.

Leuk Res. 2008 Mar;32(3):379-82. Epub 2007 Sep 4.

PMID:
17767956
33.

Reciprocal protection of Mcl-1 and Bim from ubiquitin-proteasome degradation.

Wuillème-Toumi S, Trichet V, Gomez-Bougie P, Gratas C, Bataille R, Amiot M.

Biochem Biophys Res Commun. 2007 Oct 5;361(4):865-9. Epub 2007 Jul 24.

PMID:
17681275
34.

Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen.

Campone M, Campion L, Roché H, Gouraud W, Charbonnel C, Magrangeas F, Minvielle S, Genève J, Martin AL, Bataille R, Jézéquel P.

Breast Cancer Res Treat. 2008 Jun;109(3):491-501. Epub 2007 Jul 21.

PMID:
17659439
35.

Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.

Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M.

Cancer Res. 2007 Jun 1;67(11):5418-24.

36.

Reactive plasmacytoses can mimick plasma cell leukemia: therapeutical implications.

Touzeau C, Pellat-Deceunynck C, Gastinne T, Accard F, Jego G, Avet-Loiseau H, Robillard N, Harousseau JL, Bataille R, Moreau P.

Leuk Lymphoma. 2007 Jan;48(1):207-8. No abstract available.

PMID:
17325872
37.

Significant impact of survivin on myeloma cell growth.

Romagnoli M, Trichet V, David C, Clément M, Moreau P, Bataille R, Barillé-Nion S.

Leukemia. 2007 May;21(5):1070-8. Epub 2007 Feb 22.

PMID:
17315024
38.

Rituximab in CD20 positive multiple myeloma.

Moreau P, Voillat L, Benboukher L, Mathiot C, Dumontet C, Robillard N, Hérault O, Garnache F, Garand R, Varoqueaux N, Avet-Loiseau H, Harousseau JL, Bataille R; IFM group.

Leukemia. 2007 Apr;21(4):835-6. Epub 2007 Feb 1. No abstract available.

PMID:
17268523
39.

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa AM, Sotto JJ, Wetterwald M, Dumontet C, Fuzibet JG, Azais I, Dorvaux V, Zandecki M, Bataille R, Minvielle S, Harousseau JL, Facon T, Mathiot C.

Blood. 2007 Apr 15;109(8):3489-95. Epub 2007 Jan 5.

PMID:
17209057
40.

The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.

Bataille R, Jégo G, Robillard N, Barillé-Nion S, Harousseau JL, Moreau P, Amiot M, Pellat-Deceunynck C.

Haematologica. 2006 Sep;91(9):1234-40. Review.

41.

CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642.

Descamps G, Wuillème-Toumi S, Trichet V, Venot C, Debussche L, Hercend T, Collette M, Robillard N, Bataille R, Amiot M.

J Immunol. 2006 Sep 15;177(6):4218-23.

42.

Poor ex vivo induction of T-cell responses to idiotype or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma.

Garderet L, Mazurier C, Pellat-Deceunynck C, Karim A, Baudin B, Funck-Brentano C, Bouchet S, Geffroy A, Bataille R, Gorin NC, Lopez M.

Leuk Lymphoma. 2006 Jul;47(7):1340-7.

PMID:
16923566
43.

Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells.

Menoret E, Gomez-Bougie P, Geffroy-Luseau A, Daniels S, Moreau P, Le Gouill S, Harousseau JL, Bataille R, Amiot M, Pellat-Deceunynck C.

Blood. 2006 Aug 15;108(4):1346-52. Epub 2006 Apr 25.

PMID:
16638930
44.

Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors.

Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C.

Leukemia. 2006 Jun;20(6):1130-7.

PMID:
16628189
45.

Lack of CD27 in myeloma delineates different presentation and outcome.

Moreau P, Robillard N, Jégo G, Pellat C, Le Gouill S, Thoumi S, Avet-Loiseau H, Harousseau JL, Bataille R.

Br J Haematol. 2006 Jan;132(2):168-70.

PMID:
16398651
46.

[Life in a palliative care unit: daily ethical demands].

Alonso D, Ciciarelli P, Desre D, Dutheil MO, Lefeuvre A, Mora G, Bataille R, D'Harcourt I, Schuler MO, Timonie MD, Hagnere D, Knorreck F.

Soins Gerontol. 2005 Sep-Oct;(55):25-6. French. No abstract available.

PMID:
16250384
47.

Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.

Leleu X, Le Friec G, Facon T, Amiot L, Fauchet R, Hennache B, Coiteux V, Yakoub-Agha I, Dubucquoi S, Avet-Loiseau H, Mathiot C, Bataille R, Mary JY; Intergroupe Francophone du Myélome.

Clin Cancer Res. 2005 Oct 15;11(20):7297-303.

48.

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy.

Facon T, Mary JY, Pégourie B, Attal M, Renaud M, Sadoun A, Voillat L, Dorvaux V, Hulin C, Lepeu G, Harousseau JL, Eschard JP, Ferrant A, Blanc M, Maloisel F, Orfeuvre H, Rossi JF, Azaïs I, Monconduit M, Collet P, Anglaret B, Yakoub-Agha I, Wetterwald M, Eghbali H, Vekemans MC, Maisonneuve H, Troncy J, Grosbois B, Doyen C, Thyss A, Jaubert J, Casassus P, Thielemans B, Bataille R; Intergroupe Francophone du Myélome (IFM) group.

Blood. 2006 Feb 15;107(4):1292-8. Epub 2005 Sep 20.

PMID:
16174762
49.

Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol.

Moreau P, Hullin C, Garban F, Yakoub-Agha I, Benboubker L, Attal M, Marit G, Fuzibet JG, Doyen C, Voillat L, Berthou C, Ketterer N, Casassus P, Monconduit M, Michallet M, Najman A, Sotto JJ, Bataille R, Harousseau JL; Intergroupe Francophone du Myélome group.

Blood. 2006 Jan 1;107(1):397-403. Epub 2005 Sep 6.

PMID:
16144800
50.

Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex.

Gomez-Bougie P, Oliver L, Le Gouill S, Bataille R, Amiot M.

Oncogene. 2005 Dec 1;24(54):8076-9.

PMID:
16091744

Supplemental Content

Loading ...
Support Center